2012. Reichardt P et al. – Quality of life and utility in patients with metastatic soft tissue and bone sarcoma: The Sarcoma Treatment and Burden of Illness in North America and Europe (SABINE) study
Reichardt P, Leahy M, Garcia Del Muro X, Ferrari S, Martin J, Gelderblom H, Wang J, Krishna A, Eriksson J, Staddon A, Blay JY. Quality of life and utility in patients with metastatic soft tissue and bone sarcoma: The Sarcoma Treatment and Burden of Illness in North America and Europe (SABINE) study. Sarcoma. 2012;740279.
The aim of the study was to assess health-related quality of life (HRQoL) among metastatic soft tissue (mSTS) or bone sarcoma (mBS) patients who had attained a favourable response to chemotherapy. We employed the EORTC QLQ-C30, the 3-item Cancer-Related Symptoms Questionnaire, and the EQ-5D instrument. HRQoL was evaluated overall and by health state in 120mSTS/mBS patients enrolled in the SABINE study across nine countries in Europe and North America. Utility was estimated from responses to the EQ-5D instrument using UK population-based weights. The mean EQ-5D utility score was 0.69 for the pooled patient sample with little variation across health states. However, patients with progressive disease reported a clinically significant lower utility (0.56). Among disease symptoms, pain and respiratory symptoms are common. This study showed that mSTS/mBS is associated with reduced HRQoL and utility among patients with metastatic disease.